Alcista
$19.74
Precio del escenario
$18.520
+0.091 (+0.49%)Al cierre
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
Prenetics Global Ltd is a good buy right now due to its current price of $17.35, which is well below the average analyst price target of $40. Additionally, the company has shown strong revenue growth, with Q2 2026 revenue at $46.5 million, a 29% quarter-over-quarter increase. However, the main risk is the negative net income of -9 million in Q2 2026, which reflects ongoing losses despite revenue growth.
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

IM8 Becomes Official Nutrition Partner of NBA in Southeast Asia

Prenetics Leadership's Personal Investment Reaches $3.75 Million

Prenetics Reports Significant Revenue Growth in Q2 2026

Prenetics Partners with Lily Collins as Global Ambassador

Prenetics Reports 288% Revenue Growth in Q2 2026
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8. It operates in the Healthcare sector (ACCIDENT & HEALTH INSURANCE industry).
Prenetics Global Ltd is a good buy right now due to its current price of $17.35, which is well below the average analyst price target of $40. Additionally, the company has shown strong revenue growth, with Q2 2026 revenue at $46.5 million, a 29% quarter-over-quarter increase. However, the main risk is the negative net income of -9 million in Q2 2026, which reflects ongoing losses despite revenue growth.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.